Quand Recherche sur les anticorps monoclonaux et polyclonaux rencontre Inhibition et analyse des peptidases

Hypothèse formelle

If an anti-FAP antibody is engineered with Fc mutations (S239D/I332E) to increase FcγRIIIa affinity, then FAP+ CAFs will be depleted via NK cell-mediated ADCC, leading to a measurable reduction in immunosuppressive cytokines and increased CD8+ T cell infiltration, because the enhanced Fc-FcγRIIIa interaction overcomes the low baseline ADCC activity against stromal targets.

Titre donné par l’affûteur : Fc-Engineered Anti-FAP Antibodies Enhance NK Cell-Mediated ADCC and Remodel the Immunosuppressive Tumor Microenvironment

Contre-preuves

1. This paper focuses on using FAP as a target for radiopharmaceutical therapy, not for antibody-mediated cell killing. It does not directly contradict the hypothesis but highlights an alternative approach to targeting FAP, suggesting that the field is exploring various modalities.

   Gravité mineureDesign of a Fibroblast Activation Protein–Targeted Radiopharmaceutical Therapy with High Tumor–to–Healthy-Tissue Ratios (2024)

2. This paper uses a DNA vaccine to target FAP, which induces a T-cell mediated immune response, not an NK cell-mediated ADCC response. It does not contradict the hypothesis but shows an alternative immune-based strategy for targeting FAP.

   Gravité mineureAlteration of the tumor stroma using a consensus DNA vaccine targeting Fibroblast Activation Protein (FAP) synergizes with anti-tumor vaccine therapy in mice (2017)

Inconnues et conditions de validité

Inconnues identifiées

• We do not know the threshold of FAP expression density required for efficient NK cell-mediated ADCC.
• We do not know whether the in vitro ADCC activity will translate to in vivo efficacy given the hypoxic and metabolically challenging TME.
• We do not know the extent to which CAF depletion will lead to compensatory mechanisms from other fibroblast subsets.

Conditions de validité

• FAP expression density on CAFs must be above a threshold of approximately 10,000 receptors per cell.Justification : Below this density, the avidity of the antibody-FAP interaction may be insufficient to trigger stable immunological synapse formation and NK cell activation, as shown in other ADCC models.
• The tumor microenvironment must contain or be able to recruit NK cells (CD3-CD56+).Justification : The proposed mechanism relies entirely on NK cell-mediated ADCC. In “cold” tumors with no NK cell infiltration, the antibody will be ineffective.
• The treatment is limited to tumors where FAP is expressed on CAFs and not on malignant cells.Justification : If FAP is expressed on the tumor cells themselves, the antibody may directly kill cancer cells, confounding the interpretation of the CAF-depletion mechanism.
• The Fc-engineered antibody must not induce significant systemic toxicity due to FAP expression in healthy tissues (e.g., bone marrow).Justification : FAP is expressed in some normal adult tissues. A therapeutic window must exist where tumor-associated CAFs are preferentially targeted.

Mécanisme proposé

Chaîne causale

1. Step 1: The Fc-engineered anti-FAP antibody (e.g., S239D/I332E) binds to FAP antigen on CAFs with high affinity (Kd < 10 nM) via its Fab domain.
2. Step 2: The engineered Fc domain binds to FcγRIIIa (CD16a) on NK cells with increased affinity (Kd < 100 nM), overcoming the inhibitory signals from HLA-E on CAFs.
3. Step 3: This cross-linking triggers NK cell degranulation, releasing perforin and granzyme B, leading to apoptosis of FAP+ CAFs within 4-24 hours.
4. Step 4: The depletion of FAP+ CAFs reduces the secretion of immunosuppressive cytokines (WNT2, CCL2) by >50%.
5. Step 5: Reduced CCL2 levels decrease Treg recruitment, and reduced WNT2 signaling decreases T cell exhaustion, leading to increased CD8+ T cell infiltration and function.
6. Step 6: The remodeled TME (increased CD8/Treg ratio) enhances the efficacy of checkpoint inhibitors like anti-PD-1.

Postulats clés

• FAP is expressed on the cell surface of CAFs at sufficient density (>10,000 copies/cell) for efficient ADCC.
• NK cells are present in the tumor microenvironment or can be recruited to the tumor site.
• The Fc-engineered antibody does not bind to off-target cells expressing FAP (e.g., bone marrow stromal cells) causing systemic toxicity.
• The immunosuppressive phenotype of CAFs is reversible upon their depletion, not compensated by other stromal cell types.

Cadre théorique

Antibody-dependent cell-mediated cytotoxicity (ADCC) and the cancer-immunity cycle, specifically the concept of targeting the immunosuppressive tumor stroma to relieve immune suppression and restore anti-tumor immunity.

Variables

Prédictions falsifiables

1. 1

   The S239D/I332E Fc-engineered anti-FAP antibody will induce higher ADCC against FAP+ CAFs compared to the wild-type antibody.

   Borne quantitative

   At an antibody concentration of 10 μg/mL and an E:T ratio of 10:1, the S239D/I332E variant will induce ≥ 40% specific lysis of FAP+ CAFs, compared to < 10% for the WT antibody, over a 4-hour chromium-51 release assay.

   Méthode de mesure

   Standard 4-hour 51Cr-release assay or LDH release assay using primary human NK cells (isolated from healthy donors) and FAP+ CAFs (isolated from tumor samples or differentiated from fibroblasts).Test statistique Two-way ANOVA with antibody variant and concentration as factors, followed by Tukey’s HSD post-hoc test, alpha=0.05.

   Hypothèse nulle

   H0: There is no significant difference in specific lysis between the S239D/I332E variant and the WT antibody (mean difference = 0).

2. 2

   NK cells from donors with the high-affinity FcγRIIIa V/V genotype will mediate higher ADCC with the Fc-engineered antibody than NK cells from F/F donors.

   Borne quantitative

   At an antibody concentration of 1 μg/mL and an E:T ratio of 10:1, NK cells from V/V donors will show a ≥ 2-fold increase in specific lysis of FAP+ CAFs compared to NK cells from F/F donors.

   Méthode de mesure

   Genotyping of FcγRIIIa (rs396991) by PCR-RFLP or TaqMan assay. ADCC assay as described above, comparing NK cells from V/V (n=5) and F/F (n=5) donors.Test statistique Unpaired two-tailed t-test, alpha=0.05.

   Hypothèse nulle

   H0: There is no significant difference in specific lysis between V/V and F/F donor NK cells.

3. 3

   In a xenograft model, treatment with the Fc-engineered anti-FAP antibody will reduce tumor volume and increase CD8+ T cell infiltration compared to control.

   Borne quantitative

   In a subcutaneous MC38 or HT-29 xenograft model with co-injected FAP+ CAFs, treatment with 10 mg/kg of the Fc-engineered antibody (twice weekly for 3 weeks) will result in a ≥ 50% reduction in tumor volume (mm³) and a ≥ 2-fold increase in intratumoral CD8+ T cells (cells/mm²) compared to the vehicle control group.

   Méthode de mesure

   Tumor volume measured by caliper. Tumor-infiltrating lymphocytes analyzed by flow cytometry and immunohistochemistry (IHC) for CD8 and FoxP3.Test statistique One-way ANOVA with treatment as a factor, followed by Dunnett’s post-hoc test, alpha=0.05.

   Hypothèse nulle

   H0: There is no significant difference in tumor volume or CD8+ T cell density between the Fc-engineered antibody group and the vehicle control group.

Protocole expérimental

Références

9 références, toutes issues de Semantic Scholar. Une référence vérifiée est un article qui existe et qui est indexé par Semantic Scholar. Cela ne veut pas dire qu’il confirme l’idée.

1. 1
   D. Ha, A. Tanaka, Tatsuya Kibayashi et al. (2018). Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody.appui par analogie · 178 citations · doi:10.1073/pnas.1812186116Ce qu’en retient le documentaliste An Fc-engineered anti-CTLA-4 antibody with enhanced effector function effectively depleted intratumoral Tregs, leading to increased CD8+ T cell expansion and anti-tumor immunity.Pertinence Provides a direct precedent for Fc-engineering of an antibody to enhance its cytotoxic effector function (ADCC) against an immunosuppressive cell population (Tregs) in the tumor microenvironment. This is analogous to the proposed strategy of Fc-engineering anti-FAP antibodies to deplete immunosuppressive CAFs.
2. 2
   S. Buchan, L. Dou, M. Remer et al. (2018). Antibodies to Costimulatory Receptor 4‐1BB Enhance Anti‐tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.appui par analogie · 141 citations · doi:10.1016/j.immuni.2018.09.014Ce qu’en retient le documentaliste Anti-4-1BB antibodies engineered for enhanced FcγR binding preferentially deplete intratumoral Tregs, contributing to their anti-tumor activity.Pertinence Demonstrates that the anti-tumor efficacy of an antibody can be enhanced by engineering its Fc region to deplete immunosuppressive cells (Tregs) via FcγR-mediated mechanisms. This supports the core concept of the SPORE hypothesis: Fc engineering can be used to turn an antibody into a tool for eliminating immunosuppressive cells.
3. 3
   Shichuan Hu, Jinhu Ma, C. Su et al. (2021). Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis..appui indirect · 176 citations · doi:10.1016/j.actbio.2021.09.003Ce qu’en retient le documentaliste Targeting FAP+ CAFs with engineered nanovesicles reduced immunosuppressive cell populations and increased effector T cell infiltration in tumors.Pertinence Shows that targeting FAP+ CAFs can reduce immunosuppressive cells (Tregs, MDSCs, M2 macrophages) and increase effector T cell infiltration, validating FAP+ CAFs as a therapeutic target to remodel the TME. This supports the downstream goal of the SPORE hypothesis.
4. 4
   Rongyuan Wei, Junquan Song, Chenchen Liu et al. (2025). FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity..appui direct · 37 citations · doi:10.1016/j.canlet.2025.217475Ce qu’en retient le documentaliste FAP expression in CAFs upregulates PD-L1, contributing to CD8+ T cell dysfunction and immunosuppression in the tumor microenvironment.Pertinence Directly demonstrates that FAP+ CAFs are immunosuppressive by upregulating PD-L1, which leads to T cell dysfunction. This provides a strong mechanistic rationale for eliminating FAP+ CAFs, as proposed in the SPORE hypothesis, to relieve immunosuppression.
5. 5
   A. Kraxner, F. Braun, Wei-Yi Cheng et al. (2024). Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy.appui direct · 18 citations · doi:10.3389/fimmu.2024.1352632Ce qu’en retient le documentaliste FAP+ CAF density correlates with immunosuppressive immune cell states and cytokine expression patterns in tumors.Pertinence Provides evidence that FAP+ CAFs are associated with immunosuppressive circuits that limit anti-tumor immunity, supporting the hypothesis that targeting these cells could remodel the TME.
6. 6
   Hsing Hwa Lee, Z. Al-Ogaili (2025). Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities.appui indirect · 27 citations · doi:10.3389/or.2025.1617487Ce qu’en retient le documentaliste FAP+ CAFs contribute to ECM remodeling, angiogenesis, and an immunosuppressive milieu, making them a key therapeutic target.Pertinence This review highlights the role of FAP+ CAFs in creating an immunosuppressive TME and discusses challenges in targeting FAP, providing context for the proposed approach.
7. 7
   Vidhi Khanna, Hyunjoon Kim, Wenqiu Zhang et al. (2021). Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).appui par analogie · 27 citations · doi:10.1038/s41598-021-83005-6Ce qu’en retient le documentaliste TLR7/8 agonists enhanced NK cell-mediated ADCC and improved the anti-cancer efficacy of monoclonal antibodies in vivo.Pertinence Demonstrates that enhancing NK cell-mediated ADCC can improve the anti-cancer efficacy of monoclonal antibodies. This supports the central mechanism of the SPORE hypothesis, which relies on NK cell-mediated ADCC.
8. 8
   H. Vietzen, Vera Danklmaier, A. Zoufaly et al. (2022). High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19.appui indirect · 21 citations · doi:10.1016/j.gim.2022.04.005Ce qu’en retient le documentaliste High-affinity FcγRIIIa genetic variants are associated with more potent NK cell-mediated ADCC responses.Pertinence Shows that genetic variants in FcγRIIIa (CD16a) influence the potency of NK cell-mediated ADCC. This supports the hypothesis’s prediction that FcγR polymorphisms could lead to differential patient responses to an Fc-engineered anti-FAP antibody.
9. 9
   Femke A I Ehlers, Nicky A. Beelen, M. van Gelder et al. (2021). ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response.appui indirect · 18 citations · doi:10.3390/cancers13133232Ce qu’en retient le documentaliste Combining an ADCC-inducing antibody with KIR-HLA mismatched NK cells enhances the NK cell anti-tumor response.Pertinence Demonstrates that NK cell-mediated ADCC is a key mechanism of action for a therapeutic antibody (trastuzumab) and that NK cell activity can be enhanced. This supports the feasibility of relying on NK cell ADCC for the proposed anti-FAP antibody.

Nouveauté

Score de nouveauté : 0,80 sur 1 · Verdict : jugée nouvelle

Ce score est attribué par un agent à partir des travaux trouvés. C’est une estimation, pas une mesure. Comment ce score est produit

Travaux les plus proches

• An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. (2018)Différence avec l’idée : This paper uses a T-cell engager (BiTE) format targeting FAP and CD3, engaging T cells rather than NK cells. The SPORE hypothesis specifically proposes using Fc-engineered antibodies to engage NK cells via ADCC, a distinct mechanism and cell type.
• Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma (2024)Différence avec l’idée : This work uses CAR-T cells secreting bispecific T-cell engagers to target FAP+ CAFs. The SPORE hypothesis proposes a different approach: using Fc-engineered antibodies to recruit NK cells, not T cells, for ADCC against FAP+ CAFs.
• Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma (2021)Différence avec l’idée : This is a review of CAR-T cell therapy targeting FAP. The SPORE hypothesis is distinct as it focuses on Fc-engineered antibodies and NK cell-mediated ADCC, not CAR-T cells.

Lacunes et données

Lacunes identifiées

• Direct experimental evidence for the susceptibility of FAP+ CAFs to NK cell-mediated ADCC is still missing. No paper in the provided list directly tests this.
• No data exists on the specific Fc-engineering of an anti-FAP antibody (e.g., afucosylation, S239D/I332E mutations) and its resulting ADCC activity against CAFs.
• The expression levels of NK cell ligands (e.g., MICA/B, CD155) and MHC-I on FAP+ CAFs, which would determine their susceptibility to NK cell killing, are not characterized in the provided papers.

Données disponibles

• The paper by Vietzen et al. (67c6027e0959c5f9ab0709f8cf9f72718c26516e) provides data on FcγRIIIa polymorphisms and ADCC potency, which could be used to model differential patient responses.
• The paper by Khanna et al. (222d3e68d067c458b414495a55b146029703cf06) provides data on enhancing NK cell-mediated ADCC, which could inform strategies to boost the efficacy of the proposed antibody.

Synthèse du panel

Note de consensus : 6,54/10 Moyenne des cinq notes, pondérée par la confiance que chaque relecteur déclare.

Verdict du méta-relecteur : publier

Points d’accord

• The S239D/I332E Fc engineering approach is a validated and relevant strategy for increasing FcγRIIIa affinity and potentially overcoming the low ADCC susceptibility of stromal cells such as FAP+ CAFs.
• The three-phase experimental design, with predefined quantitative GO/NO-GO criteria, is a major methodological strength, enabling effective de-risking and rigorous evaluation of the hypothesis.
• Targeting FAP+ CAFs represents a relevant differentiation strategy within the immunosuppressive tumour microenvironment, with translational potential and a substantial addressable market in stroma-rich tumours.

Points de désaccord

• The principal disagreement concerns the physiological relevance of the model and the underlying hypothesis regarding the presence and functionality of NK cells in “cold” desmoplastic tumours, which the Contrarian judges to be a fatal flaw, whereas the other experts consider it a risk to be mitigated.
• A second point of divergence concerns the sufficiency of CAF depletion to induce the predicted immune remodelling, with the Contrarian and the domain expert emphasising the redundancy of cytokine sources (e.g., TAMs) and potential compensatory mechanisms, while the Methodologist and the Industry reviewer view the causal chain as plausible and testable.
• Finally, the question of potential off-target toxicity (non-tumoural FAP+) is a shared concern, but with differing implications: the Industry reviewer and the funding strategist see it as a development risk to be managed, whereas the Contrarian regards it as a potential obstacle not resolved by the current protocol.

Chemin critique

The most decisive factor for the success of this hypothesis is the experimental validation of the presence and functionality of NK cells in the targeted desmoplastic tumour microenvironment. Without a demonstration that NK cells can be recruited and activated in situ (or that their absence can be compensated for), the efficacy of ADCC, even when optimised through Fc engineering, remains a solution to a problem that may not exist in “cold” tumours.

Recommandation finale

The panel recommends publication of the brief for experimental validation, as the hypothesis is judged mechanistically sound, methodologically rigorous, and strategically relevant. However, publication should be conditional on a revision that explicitly incorporates the major concerns: 1) a formal statistical justification (power analysis) for the in vivo phase, 2) a detailed plan for assessing NK cell density and function in tumour models, and 3) a strategy for monitoring and mitigating potential systemic toxicity. The protocol should also include controls for cytokine redundancy and compensatory mechanisms. These additions are essential to transform a promising hypothesis into an experimental plan capable of yielding conclusive data and addressing the most severe criticisms.